<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646750</url>
  </required_header>
  <id_info>
    <org_study_id>GELTAMO-Z-BEAM LDGGB</org_study_id>
    <secondary_id>EudraCT No.: 2007-003198 - 22</secondary_id>
    <nct_id>NCT00646750</nct_id>
  </id_info>
  <brief_title>Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom</brief_title>
  <acronym>Z-BEAM LDGGB</acronym>
  <official_title>Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-cell Diffuse Lymphom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy (complete response rate) of Ybritumomab Tiuxetan (Zevalin)
      administration in the conditioning treatment of patients with refractory large B-cell diffuse
      lymphoma submitted to autologous transplantation of peripheral blood haematopoietic stem
      cells.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease clinical response to treatment - complete response rate.</measure>
    <time_frame>Pre-transplantation; post-transplantation (one week following Ybritumomab Tiuxetan (Zevalin) administration); And three months post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haematopoietic and extra-haematopoietic toxicity of the Ybritumomab Tiuxetan (Zevalin) plus BEAM regimen.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete + partial response)</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transplantation haematological and immunological reconstitution</measure>
    <time_frame>Until post-transplantation day +100</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEAM preceded by Ybritumomab Tiuxetan (Zevalin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)</intervention_name>
    <description>Day -21: rituximab. 250 mg/m2 iv
Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).
Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ybritumomab Tiuxetan (Zevalin)</other_name>
    <other_name>Rituximab (Mabthera)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Give their written informed consent.

          2. Abide by at least one of the following conditions:

               -  Obtain no partial response after first-line chemotherapy including anthracyclines
                  + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else

               -  Absence of partial response after having received salvage (post-induction)
                  chemotherapy including R-IFE, R-ESHAP, R-ICE or the like.

               -  Patients on first recidivation who do not attain partial remission after salvage
                  chemotherapy.

               -  Patients with transformed lymphoma, on first partial remission (No CR).

          3. Stable disease at the time of transplantation.

          4. Age ≥ 18 but ≤ 70.

          5. Life expectancy of greater than three months.

        Additionally, to be able to undergo haematopoietic stem cell transplantation, all patients
        should satisfy the requirements of routine clinical practice, i.e.:

          1. Performance status (ECOG) &lt; 3.

          2. FEV1, DLCO and FVC ≥ 50% of the normal theoretical values.

          3. Ventricular ejection fraction (through echocardiography or isotope ventriculography) ≥
             50%.

          4. Total bilirubin and transaminases &lt; 3 times the normal maximum value, except if
             attributable to the underlying disease.

          5. Creatinine &lt; 2 times the maximum normal value, and creatinine clearance &gt; 40 ml/min,
             except if attributable to the underlying disease.

          6. Absence of symptomatic heart disease, cirrhosis or active B or C virus hepatitis.

          7. HIV negative.

        Exclusion Criteria:

          1. Impossibility of collecting, via apheresis, a number of CD34+ cells ≥ 2 x 106/kg.

          2. Known hypersensitivity to mouse proteins.

          3. Involvement of CNS by lymphoma.

          4. Progressive lymphoma during the month prior to the date of transplantation.

          5. Previous radioimmunotherapy.

          6. Previous autologous transplantation of haematopoietic stem cells.

          7. Pregnant or breastfeeding women, or adults of childbearing age who are not using an
             effective contraceptive method.

          8. Being submitted to treatment in a clinical trial for 30 days prior to entry in this
             trial.

          9. Active psychiatric disease, including addiction disorders.

         10. Existence of active not-haematopoietic neoplasia, with the exception of cutaneous
             basal carcinoma or cervix intraepithelial carcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Briones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Caballero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H.U. Central de Asturias, Oviedo</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología,</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Puerta de Hierro,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. 12 de Octubre,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Gregorio Marañón,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Internacional</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Z-BEAM</keyword>
  <keyword>Autologous</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>GELTAMO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

